(NVS/REGN)—On AGN’s UBS webcast, executives touted a wide array of ophthalmology programs, but mentioned DARPIN for AMD/DME only when asked about it. This reinforced my impression is that that AGN does not have high hopes for DARPIN.
AGN’s CEO quickly rebutted my viewpoint on this…
We do have high hope, in Ph3 for up to 12wks dose, need to be patient for the data; recruit exceeding expectations https://t.co/mvMxZBjlYG
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.